Challenging the Biotech Business Model
By Fintan Walton
Pharma Deals Review: Vol 2006 Issue 73 (Table of Contents)
Published: 1 Jul-2006
DOI: 10.3833/pdr.v2006.i73.495 ISSN: 1756-7874
Section: Business Commentaries
Fulltext:
Abstract
Traditionally, a biotech's series of funding rounds ultimately led to a public listing or initial public offering (IPO). Recently, however, things have changed, and the number of biotech companies being acquired by larger pharmaceutical companies, or who have merged with an already listed company, has increased dramatically.
Copyright: © IQVIA 2018
Last Issue PDF
RSS